High-risk Ewing's sarcoma: end-intensification using autologous bone marrow transplantation

Area of Science:

• Oncology
• Clinical Trials
• Cancer Research

Background:

• Retrospective analysis indicated a correlation between primary tumor size and patient survival.
• A prospective study was initiated to validate this hypothesis.
• Treatment protocols were stratified based on tumor size and metastatic status.

Purpose of the Study:

• To prospectively evaluate the impact of primary tumor size on survival.
• To compare the efficacy of different treatment protocols, including standard-risk, HR-2, and HR-3.
• To assess the effectiveness of adjuvant chemotherapy, radiotherapy, surgery, and autologous bone marrow transplantation.

Main Methods:

• Patients were assigned to a standard-risk protocol (tumor size ≤ 8 cm, no metastases) or high-risk protocols.
• Standard-risk protocol involved adjuvant chemotherapy (vincristine, cyclophosphamide, doxorubicin, dactinomycin) plus radiotherapy or surgery.
• High-risk protocols (HR-2 and HR-3) included intensified chemotherapy regimens and autologous bone marrow transplantation (ABMT), with HR-3 involving total body irradiation and intensive chemotherapy prior to ABMT.

Main Results:

• The 2-year disease-free survival rates were 70% for the standard-risk protocol, 20% for HR-2, and 80% for HR-3.
• Protocol HR-2 demonstrated poor outcomes.
• Protocol HR-3 showed promising preliminary results despite a short follow-up period.

Conclusions:

• The study successfully prospectively tested the hypothesis linking tumor size to survival.
• Protocol HR-3, incorporating intensive chemotherapy and autologous bone marrow transplantation, yielded superior disease-free survival compared to HR-2.
• The promising results of HR-3 warrant further investigation in clinical trials for optimizing cancer treatment.